Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Monday

Posted by ABMN Staff on Mar 22nd, 2025

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.65) per share for the quarter.

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.15. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Trading Down 1.5 %

Shares of SGMT stock opened at $3.99 on Friday. The stock has a 50 day moving average of $4.10 and a two-hundred day moving average of $4.47. Sagimet Biosciences has a 12 month low of $2.39 and a 12 month high of $7.38. The company has a market capitalization of $122.39 million, a P/E ratio of -2.79 and a beta of 2.57.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on SGMT shares. Oppenheimer assumed coverage on Sagimet Biosciences in a report on Friday, December 6th. They set an “outperform” rating and a $30.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $32.00 price target on shares of Sagimet Biosciences in a report on Tuesday, March 11th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.00.

View Our Latest Report on Sagimet Biosciences

Sagimet Biosciences Company Profile

(Get Free Report)

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.